BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed price. Currency in USD
47.46
+0.48 (+1.02%)
At close: 4:00PM EDT

47.50 +0.04 (0.08%)
After hours: 6:10PM EDT

Stock chart is not supported by your current browser
Previous close46.98
Open47.08
Bid47.30 x 900
Ask47.69 x 1800
Day's range47.02 - 47.83
52-week range42.48 - 63.69
Volume7,584,605
Avg. volume13,263,922
Market cap77.634B
Beta (3Y monthly)0.71
PE ratio (TTM)12.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.64 (3.49%)
Ex-dividend date2019-07-03
1y target estN/A
Trade prices are not sourced from all markets
  • Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
    Zacks

    Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

    Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

  • Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
    Zacks

    Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC

    Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.

  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
    Zacks

    Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth

    Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

  • Investing.com

    Stocks - Tilray, Canada Goose, Luckin Coffee Fall Premarket

    Investing.com - Stocks in focus in premarket trading on Wednesday:

  • Should Value Investors Pick Bristol-Myers Squibb (BMY) Stock?
    Zacks

    Should Value Investors Pick Bristol-Myers Squibb (BMY) Stock?

    Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.

  • Motley Fool

    Why Nektar Therapeutics Stock Is Crashing Today

    The biotech's manufacturing problems with a key experimental drug and uncertainty about a major partnership are rattling investors.

  • AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
    Zacks

    AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag

    AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.

  • Zacks

    Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss

    Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.

  • Top Research Reports: Bristol-Myers, CME Group, Chubb & More
    Zacks

    Top Research Reports: Bristol-Myers, CME Group, Chubb & More

    Top Research Reports: Bristol-Myers, CME Group, Chubb & More

  • Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
    Zacks

    Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss

    Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

  • Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
    Zacks

    Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold

    Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.

  • Celgene Continues Growing While Waiting for its Acquisition to Close
    Motley Fool

    Celgene Continues Growing While Waiting for its Acquisition to Close

    Bristol-Myers is getting an even bigger cash cow.

  • Do Institutions Own Bristol-Myers Squibb Company (NYSE:BMY) Shares?
    Simply Wall St.

    Do Institutions Own Bristol-Myers Squibb Company (NYSE:BMY) Shares?

    Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups...

  • Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
    Zacks

    Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

    Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

  • 4 High Earnings Yield Stocks to Strengthen Your Portfolio
    Zacks

    4 High Earnings Yield Stocks to Strengthen Your Portfolio

    Earnings yield is very useful for determining undervalued stocks.

  • Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
    Zacks

    Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines

    Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.

  • Is a Beat in Store for Nektar (NKTR) This Earnings Season?
    Zacks

    Is a Beat in Store for Nektar (NKTR) This Earnings Season?

    The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.

  • Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
    Zacks

    Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

    Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

  • Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance
    Zacks

    Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance

    Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.

  • Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
    Zacks

    Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss

    Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.

  • Merck Has a Problem Every Drugmaker Wishes It Had
    Bloomberg

    Merck Has a Problem Every Drugmaker Wishes It Had

    (Bloomberg Opinion) -- Merck & Co. has a problem, but it’s the kind of problem the rest of the pharmaceutical world  wish they had.  The drugmaker released second-quarter earnings and revenue figures Tuesday that smashed Wall Street expectations and prompted a significant boost to full-year guidance. The driver – as always for Merck – was blockbuster immune-boosting cancer treatment Keytruda. Sales of the medicine, which is approved to treat a wide variety of cancers, were $2.6 billion in the latest quarter, 58% higher than a year earlier. Keytruda’s performance was so good, its year-over-year growth exceeded the second-quarter sales of all but one other Merck franchise. Therein lies the issue: Merck is already over-dependent on Keytruda and is poised to become even more so. That’s generally not good. But because the drug is so successful the company will have a long and well-funded grace period to find a solution. So it could be worse.Keytruda’s present is pretty fabulous. Its future looks even brighter. Merck recently announced that the drug succeeded in a breast-cancer trial, while rival Bristol-Myers Squibb Co.’s Opdivo produced mixed data that will hamper it in the crucial lung market. Peak sales estimates for Keytruda have crept over $20 billion, and I can’t call that entirely crazy. The drug isn’t invincible. It has failed trials in liver and gastric cancer, and Merck can’t entirely dismiss competition with five similar medicines on the market and more on the way. There’s always a chance that an innovative new treatment could leapfrog Keytruda. And Merck and its shareholders must know that relying too heavily on even an excellent product is unwise.Merck isn’t entirely bereft of other drugs. It has a solid vaccine unit and a promising HIV medicine in development. But the company doesn’t appear to have anything coming in its pipeline that would contribute anything near Keytruda’s growth and value anytime soon.At the end of the day, either Keytruda is best in a highly lucrative category, or Merck is best in class at executing a strategy to expand its use. Further years of splendid sales growth seem more likely than not. That doesn’t absolve Merck of the need to act and bolster its pipeline. But it does allow management to be relatively patient and look for value instead of overpaying for late-stage assets or gambling on a risky mega-merger. It had best not wait too long, however. Big pharma does seem to have a knack for flubbing efforts to replace big blockbusters, even when they have years of notice. Success breeds complacency, and Merck will regret it if it wastes the next few years.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
    Zacks

    Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Investing.com

    Celgene Rises as European Commission OKs Merger With Bristol-Myers

    Investing.com - Celgene (NASDAQ:CELG) was higher in midday trade on Monday after the European Union Commission gave its blessing for the biopharmaceutical company to merge with Bristol-Myers Squibb (NYSE:BMY).

  • Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
    Zacks

    Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?

    Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes